Results 1 - 20 of 844 in Genentech
-
... such as Office and beat back a challenge for Procter & Gamble Co.'s business this year. Google won clients such as Genentech Inc., and D.C. provides a glimpse into how the Web company is gaining ground. What the article doesn't cover is how well the ...
Comment?
-
Phase III Study Showed Rituxan In Combination With Chemotherapy...
... for most patients. Over the past ten years, there have been more than one million patient exposures to Rituxan. Genentech and Biogen Idec co-market Rituxan in the United States, and Roche markets MabThera in the rest of the world, except Japan, ...
Comment?
-
... companies in the sector. The journal "Science" is out with its annual ranking of the best biopharma employers. And Genentech ( DNA ) has grabbed the top position again. It had been #1 for the first five years of the survey, but fell to #2 last year, ...
Comment?
-
Two new PDL directors get cash, options
... thousands of shares. John McLaughlin, the former CEO of Anesiva Inc. (NASDAQ: ANSV) and former general counsel at Genentech Inc. (NYSE: DNA), and former Boston Scientific Corp. (NYSE: BSX) executive Paul Sandman joined the board of the Redwood ...
Comment?
-
Google Rewires Washington in Challenge to Microsoft's Top Office Software
... such as Office and beat back a challenge for Procter & Gamble Co.'s business this year. Google won clients such as Genentech Inc., and D.C. provides a glimpse into how the Web company is gaining ground. ``If Google keeps getting big customers like ...
Comment?
-
Monsanto Recognized as Top Biotechnology Employer by Science Magazine
... environment, work/life balance, and compensation and benefits. Monsanto ranked second only to San Francisco -based Genentech Inc. Monsanto was recently honored as one of the 2008 Working Mother 100 Best Companies by Working Mother magazine. ...
Comment?
-
Gene-testing startup's study responds to critics
A Silicon Valley gene-testing startup is responding to criticism that the tests could spur bad health-care choices by teaming up for a broad study of how the results affect behavior.
Comment?
-
Option Update: Genentech volatility elevated; shares below Roche's $89 offer
Genentech closed at $78.19 Tuesday. Roche announced on July 21 the offer to buy the balance of 44% of DNA it does not own for $89 cash.
Comment?
-
Extending time of stroke drug treatment OK
... Boehringer Ingelheim Pharmaceuticals Inc., which markets TPA as Actilyse overseas. TPA is sold in North America by Genentech Inc. as Activase. Last week, the same researchers reported similar results in a less rigorous observational study of 664 ...
Comment?
-
Drug stocks slide with broader market
... amongst the large caps included Schering-Plough Corp. ( SGP : SGP , , ) , Abbott Laboratories ( ABT : ABT , , ) , Genentech Inc. ( DNA : DNA , , ) , AstraZeneca PLC ( AZN : AZN , , ) and Novartis AG. ( NVS : NVS , , )
Comment?
-
Morgan Sheng Appointed VP Neuroscience Research at Genentech
Genentech, Inc. has appointed Morgan Sheng, MD, PhD, vice president, neuroscience.
Comment?
-
Rituxan Plus Chemotherapy Effective For Leukemia Treatment
Rituxan is found to be a good blood cancer treatment method given together with traditional chemotherapy. Genentech Inc. and Biogen Idec conducted a late stage trial called REACH and involving 552 chronic lymphocytic leukemia patients, who had ...
Comment?
-
NEWS & NOTES: Kit makes wheelchairs ATVs
... month. Watkins' final grade at the end of the semester? An A. Tarceva, Avastin combo no help Roche Holding AG and Genentech Inc. said recently that a study into the benefits of combining their Tarceva and Avastin drugs for lung cancer patients did ...
Comment?
-
Phase III Study of Rituxan in Leukemia Meets its Goal
Genentech Inc. and Biogen Idec Inc. said their investigational leukemia drug Rituxan passed a second Phase III study, meeting its primary goal of improving the period of time before the disease progresses ...
Comment?
-
Genentech touts test of Rituxan plus chemo vs. leukemia
Biotech giant Genentech Inc. and partner Biogen Idec said a combined treatment of Rituxan and chemotherapy did well in patients with chronic lymphocytic leukemia, the most common adult leukemia.
Comment?
-
Phase III Study Showed Rituxan Combined With Chemotherapy Improved...
... for most patients. Over the past ten years, there have been more than one million patient exposures to Rituxan. Genentech and Biogen Idec co-market Rituxan in the United States, and Roche markets MabThera in the rest of the world, except Japan, ...
Comment?
-
Genentech, Inc. , Biogen Idec, Inc. (Massachusetts)'s Rituxan Meets...
Genentech Inc. and Biogen Idec Inc. said Tuesday their cancer drug Rituxan slowed the progress of chronic lymphocytic leukemia in a late stage clinical trial, meeting its primary goal.
Comment?
-
Genes May Explain Racial Disparities in Asthma
... as severe by their physicians and to be treated with three or more long-term controller drugs, Haselkorn, of Genentech Inc., in South San Francisco, California, and her associates report in the Annals of Allergy, Asthma and Immunology. However, the ...
Comment?
-
Genentech, Biogen Idec report positive study results for Rituxan in...
Genentech, Biogen Idec report positive study results for Rituxan in combination with chemotherapy in chronic lymphocytic leukemia patients M2Europharma on Tuesday, 07 October 2008 at 07:51 GMT 7 October 2008 US ...
Comment?
-
Genentech and OSI Pharmaceuticals Announce Topline Results from Phase ...
October 5, 2008 -- Genentech, Inc. and OSI Pharmaceuticals, Inc. today announced that a randomized Phase III study evaluating Avastin in combination with Tarceva in patients with advanced non-small cell lung ...
Comment?
Genentech Forum
Most Popular
